InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（8 笔）
内部人交易记录
首席财务官已披露买入
2
已披露卖出
8
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Goldan Keith A., 首席财务官. Officer active across 4 companies, notably OptiNose, Inc.. Cumulatively, 18 disclosures have been recorded. Breakdown: 2 buys · 8 sells. Total volume traded: €176k. Activity tracked since 17 June 2021. The latest transaction was filed on 1 April 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Goldan Keith A.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
32,751 股0Common StockSEC:0001493152-26-015456:0
3,410 股@ US$21.02831.1% 占其流量Common StockSEC:0001193125-26-043813:0
1,219 股@ US$8.484.4% 占其流量Common StockSEC:0001193125-26-041497:0
1,224 股0Common StockSEC:0001193125-25-303941:0
1,226 股@ US$8.437.2% 占其流量Common StockSEC:0000950170-25-105258:0
1,296 股@ US$9.2858.9% 占其流量Common StockSEC:0000950170-25-096948:0
3,000 股Common StockSEC:0000950170-25-074304:0
标准退出：2025年8月17日 (T+90)
3,777 股@ US$15.50453.5% 占其流量Common StockSEC:0000950170-25-019005:0
18,500 股0Common StockSEC:0000950170-25-016389:0
1,250 股@ US$20.029821.9% 占其流量Common StockSEC:0001562180-24-005118:0
标准退出：2024年9月12日 (T+90)
862 股@ US$18.1213.4% 占其流量Common StockSEC:0001562180-24-001222:0
577 股@ US$22.3111.2% 占其流量Common StockSEC:0001562180-23-005152:0
3,205 股0Common StockSEC:0001562180-22-005117:0
4,617 股@ US$2.1168.9% 占其流量Common StockSEC:0001494650-22-000029:0
56,730 股0Common StockSEC:0001494650-22-000006:0
580 股@ US$1.646.5% 占其流量Common StockSEC:0001494650-21-000155:0
578 股@ US$2.78910.6% 占其流量Common StockSEC:0001494650-21-000108:0
576 股@ US$3.7314.0% 占其流量Common StockSEC:0001494650-21-000076:0
18 条申报中的 18 条
About Goldan Keith A.
Goldan Keith A. is Chief Financial Officer. He has 18 filings in total, and across the sampled recent filings from 2021-06-17 to 2026-04-07, the amounts shown are EUR 23315 in purchases and EUR 152593 in sales, mainly in Syndax Pharmaceuticals Inc, with filings also for OptiNose, Inc. and Abeona Therapeutics INC.
